Induction of 4-1BB (CD137) expression by DNA damaging agents in human T lymphocytes

被引:17
作者
Kim, KM
Kim, HW
Kim, JO
Baek, KM
Kim, JG
Kang, CY
机构
[1] Seoul Natl Univ, Immunol Lab, Coll Pharm, Seoul 151742, South Korea
[2] Seoul Natl Univ, Coll Med, Seoul 151742, South Korea
关键词
D O I
10.1046/j.1365-2567.2002.01538.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
4-1BB(CD137) is a member of the tumour necrosis factor receptor superfamily and is expressed on activated T cells, monocytes and natural killer (NK) cells. The interaction of 4-1BB and 4-1BB ligand provides a costimulatory signal leading to T-cell activation. The expression of 4-1BB has been known to be activation dependent. Interestingly, we found that expression of 4-1BB increased in human peripheral blood mononuclear cells after exposure to mitomycin C. Thus, we tested whether the treatment with other DNA-damaging agents, such as doxorubicin, bleomycin, and gamma-irradiation, could induce 4-1BB expression. The data indicated that 4-1BB expression increased dose-dependently by these agents reaching maximum at 2-3 days after the exposure. We found that the major 4-1BB-expressing population was CD3(+) T cells, although a moderate number of CD14(+) cells and a few NKB1(+) cells also expressed 4-1BB. The levels of 4-1BB expression induced by anticancer drugs, were relatively lower than that induced by CD3 ligation. Interestingly, at subcytotoxic concentrations, doxorubicin and bleomycin considerably enhanced 4-1BB expression induced by CD3 ligation in CEM cells. The ligation of the damage-induced 4-1BB by monoclonal antibody enhanced the viability and proliferating capacity of the cells. In conclusion, the expression of 4-1BB might be one of the cellular responses of the immune cells against various genotoxic stresses.
引用
收藏
页码:472 / 479
页数:8
相关论文
共 55 条
[1]   MOLECULAR AND BIOLOGICAL CHARACTERIZATION OF HUMAN 4-1BB AND ITS LIGAND [J].
ALDERSON, MR ;
SMITH, CA ;
TOUGH, TW ;
DAVISSMITH, T ;
ARMITAGE, RJ ;
FALK, B ;
ROUX, E ;
BAKER, E ;
SUTHERLAND, GR ;
DIN, WS ;
GOODWIN, RG .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1994, 24 (09) :2219-2227
[2]   TUMOR-NECROSIS-FACTOR RECEPTOR SUPERFAMILY MEMBERS AND THEIR LIGANDS [J].
ARMITAGE, RJ .
CURRENT OPINION IN IMMUNOLOGY, 1994, 6 (03) :407-413
[3]   Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer [J].
Bass, KK ;
Mastrangelo, MJ .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1998, 47 (01) :1-12
[4]   ACTIVE IMMUNOTHERAPY OF HUMAN-MELANOMA EXPLOITING THE IMMUNOPOTENTIATING EFFECTS OF CYCLOPHOSPHAMIDE [J].
BERD, D ;
MASTRANGELO, MJ .
CANCER INVESTIGATION, 1988, 6 (03) :337-349
[5]   CD137 expression in tumor vessel walls - High correlation with malignant tumors [J].
Broll, K ;
Richter, G ;
Pauly, S ;
Hofstaedter, F ;
Schwarz, H .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2001, 115 (04) :543-549
[6]  
Chu NR, 1997, J IMMUNOL, V158, P3081
[7]   ROLE OF 4-1BB-LIGAND IN COSTIMULATION OF T-LYMPHOCYTE GROWTH AND ITS UP-REGULATION ON M12 B-LYMPHOMAS BY CAMP [J].
DEBENEDETTE, MA ;
CHU, NR ;
POLLOK, KE ;
HURTADO, J ;
WADE, WF ;
KWON, BS ;
WATTS, TH .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 181 (03) :985-992
[8]  
DeBenedette MA, 1997, J IMMUNOL, V158, P551
[9]   Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells [J].
Futagawa, T ;
Akiba, H ;
Kodama, T ;
Takeda, K ;
Hosoda, Y ;
Yagita, H ;
Okumura, K .
INTERNATIONAL IMMUNOLOGY, 2002, 14 (03) :275-286
[10]   4-1BB is expressed on CD45RA(hi)RO(hi) transitional T cell in humans [J].
GarniWagner, BA ;
Lee, ZH ;
Kim, YJ ;
Wilde, C ;
Kang, CY ;
Kwon, BS .
CELLULAR IMMUNOLOGY, 1996, 169 (01) :91-98